Pending Class Action Lawsuit for Enochian Biosciences Stockholders Announced

Overview of the Class Action Lawsuit Against Enochian Biosciences

In a significant move for investors, a class action lawsuit has been initiated concerning Enochian Biosciences Inc. This lawsuit is aimed at individuals or entities that bought or acquired Enochian common stock between January 17, 2018, and June 27, 2022. The case is presided over by Judge John W. Holcomb in the Central District of California, under case number 822-cv-01374-JWH-JDE.

Key Details of the Litigation

Albert Chow has stepped forward as the plaintiff on behalf of all affected parties, claiming damages caused by the alleged misconduct related to the company’s governance and disclosures during the specified period. The class action aims to address the grievances of shareholders who suffered losses during this timeframe.

As part of the litigation process, a settlement amounting to $2.5 million has been proposed to resolve the claims made in the lawsuit. A crucial court hearing on this settlement will take place on November 25, 2025, at the Ronald Reagan Federal Building and U.S. Courthouse in Santa Ana, California. Investors are urged to consider their involvement as the outcome will directly influence the claims and payouts related to the settlement.

What Investors Should Know

1. Potential Benefits: If the settlement is approved, those who qualify within the settlement class stand to receive compensation, which is contingent upon the finalization of the settlement arrangement.
2. Requirements for Participation: Investors looking to participate in the potential compensation must submit a Proof of Claim and Release form by December 7, 2025. Failure to do so might lead to forfeiting any rights to payout from the settlement fund.
3. Exclusion and Objections: If any shareholders wish to opt-out of the settlement class, they must file a request by October 23, 2025. Additionally, stakeholders can voice any objections regarding the settlement or the legal fees proposed to be paid to counsel representing the plaintiffs until November 4, 2025.

How to Stay Informed

For those interested in understanding more about their options and rights, the Long-Form Notice detailing crucial information is accessible on www.EnochianSecuritiesLitigation.com. This site provides outlines of the litigation’s context and the expectations leading to the hearing and proposed settlement.

Contact Information for Further Queries

Questions and clarifications regarding the lawsuit can be directed to the Claims Administrator, either through email at [email protected], or by telephone at (888) 658-8895. It’s essential for affected shareholders to stay informed about developments in this case, as it could significantly affect outcomes associated with their investments in Enochian Biosciences.

Conclusion

This class action underscores the importance of corporate transparency and shareholder rights within the realm of public trading. As proceedings progress, all individuals and entities involved are encouraged to remain engaged and proactive in their claim process. Ensuring proper action is taken could lead to recovery efforts for those who believe they were wronged in their investment decisions related to Enochian Biosciences.